Quantum BioPharma Ltd. Expense From Share-based Payment Transactions With Employees
Quantum BioPharma Ltd. (QNTM) reported Expense From Share-based Payment Transactions With Employees of $2.95 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-26.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees · last filed 2026-03-26
CAD
| Period end | Expense From Share-based Payment Transactions With Employees 12 month |
|---|---|
| 2019-12-31 | 16.06M CAD 40-F/A · filed 2020-03-17 |
| 2018-12-31 | 6.44M CAD 40-F/A · filed 2020-03-17 |
USD
| Period end | Expense From Share-based Payment Transactions With Employees 3 month | Expense From Share-based Payment Transactions With Employees 6 month | Expense From Share-based Payment Transactions With Employees 9 month | Expense From Share-based Payment Transactions With Employees 12 month |
|---|---|---|---|---|
| 2025-12-31 | $808.45K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | $1.80M derived: sum of 2 quarters · filed 2026-03-26 | $2.65M derived: sum of 3 quarters · filed 2026-03-26 | $2.95M 20-F · filed 2026-03-26 |
| 2025-09-30 | $996.19K 6-K · filed 2025-11-06 | $1.85M derived: sum of 2 quarters · filed 2025-11-06 | $2.14M 6-K · filed 2025-11-06 | $2.05M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | $849.58K 6-K · filed 2025-08-07 | $1.14M 6-K · filed 2025-08-07 | $1.06M derived: sum of 3 quarters · filed 2026-03-26 | $1.12M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | $291.27K 6-K/A · filed 2025-06-16 | $208.79K derived: sum of 2 quarters · filed 2026-03-26 | $274.22K derived: sum of 3 quarters · filed 2026-03-26 | $385.74K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | -$82.48K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | -$17.05K derived: sum of 2 quarters · filed 2026-03-26 | $94.47K derived: sum of 3 quarters · filed 2026-03-26 | $152.21K 20-F · filed 2026-03-26 |
| 2024-09-30 | $65.42K 6-K · filed 2025-11-06 | $176.95K derived: sum of 2 quarters · filed 2025-11-06 | $234.69K 6-K · filed 2025-11-06 | $334.07K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | $111.52K 6-K · filed 2025-08-07 | $169.27K 6-K · filed 2025-08-07 | $268.65K derived: sum of 3 quarters · filed 2026-03-26 | $394.81K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | $57.74K 6-K/A · filed 2025-06-16 | $157.13K derived: sum of 2 quarters · filed 2026-03-26 | $283.29K derived: sum of 3 quarters · filed 2026-03-26 | $686.68K derived: sum of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | $99.38K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | $225.55K derived: sum of 2 quarters · filed 2026-03-26 | $628.94K derived: sum of 3 quarters · filed 2026-03-26 | $3.84M 20-F · filed 2026-03-26 |
| 2023-09-30 | $126.16K 6-K · filed 2024-11-12 | $529.56K derived: sum of 2 quarters · filed 2024-11-12 | $3.74M 6-K · filed 2024-11-12 | |
| 2023-06-30 | $403.39K 6-K/A · filed 2024-08-19 | $3.61M 6-K/A · filed 2024-08-19 | ||
| 2022-12-31 | $1.53M 20-F/A · filed 2025-03-31 | |||
| 2021-12-31 | $7.44M 20-F · filed 2024-04-02 | |||
| 2020-12-31 | $8.05M 20-F · filed 2023-03-31 | |||
| 2019-12-31 | $12.08M 40-F · filed 2021-03-17 |